Rapid response on facial psoriasis to bimekizumab: case series

Nicoletta Bernardini, Annunziata Dattola, Giacomo Caldarola, Diego Orsini, Chiara Assorgi, Alessandra D’Amore, Giulia Maretti, Antonio Giovanni Richetta, Ersilia Tolino, Nevena Skroza, Concetta Potenza


Psoriasis is a chronic inflammatory disease that can affect any part of the body but, when it appears in certain areas, like the face, it can have a very significant psychological impact. Biologics, in particular IL-17 and IL-23 drug inhibitors, have shown relevant clinical efficacy in the management of psoriatic lesions in difficult-to-treat areas. In post hoc analysis of phase III trials in plaque psoriasis, bimekizumab has shown safety and complete clearance of high-impact areas. However, these studies did not focus on the effect of bimekizumab on facial lesions. Therefore, this case series represents the first clinical real-life experience of rapid and successful management of facial psoriasis with bimekizumab in six patients.

Article Details

Article Type

Case Series



Publication Dates

Accepted: ; Published: .


Bernardini N, Dattola A, Caldarola G, Orsini D, Assorgi C, D’Amore A, Maretti G, Richetta AG, Tolino E, Skroza N, Potenza C. Rapid response on facial psoriasis to bimekizumab: case series. Drugs Context. 2024;13:2024-1-4. https://doi.org/10.7573/dic.2024-1-4

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.